For precision medicine, profiling protein biomarkers is the way to properly diagnose and select patients for drug testing in clinical trials. In a time when it can cost $5B USD to develop a single drug and still face a 95% chance of failure, we need highly accurate testing solutions. PhasiQ’s proprietary Micropatterned Phase-Separation Technology enables scientists to measure biomarker protein levels via multiplex immunoassay. PhasiQ allows multiplexing cost-effectively without cross-reactions. In this way, our technology accelerates protein diagnostics and therapeutics development.
Shuichi Takayama, PhD – Founder & CEO
Jim Vincke, MBA – CFO
John Dishinger, PhD – Director of Product Development
Dunrie Greiling, PhD – Director of Marketing and Software